Compare BioNano Genomics Inc (BNGO) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Nano Dimension Ltd - ADR — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $314.71M). The key difference: Nano Dimension Ltd - ADR is far larger — about 23.8× BioNano Genomics Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NNDM | |
|---|---|---|
Market Cap | $13.20M | $314.71M |
Sector | Health | Technology |
52-Week High | $4.92 | $2.14 |
52-Week Low | $1.09 | $1.21 |
Enterprise Value | $15.81M | -$94.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Nano Dimension (NNDM) trades at $1.48, down 1.33% with a bearish technical signal. The company reported Q1 2026 revenue of $102.44M but a net loss of -$293.30M, reflecting a -286.72% margin. Cash burn remains high at -$101.28M from operations. Recent news highlights board disputes with shareholder Murchinson and a proposed merger with Infinite Epigenetics, creating uncertainty.
The outlook is challenged by persistent losses and negative cash flow, though the P/B of 0.64 suggests undervaluation. Risks include execution on strategic plans and shareholder activism. Analyst sentiment is cautious given the lack of profitability and ongoing corporate governance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
